Buprenorphine, sold under the brand names Subutex and Suboxone, treats opioid addiction. It is itself an opioid and can be misused, which is why the DEA limits its diversion to the streets.
Research shows buprenorphine reduces the risk of overdose by 50 percent and doubles patients’ likelihood of long-term recovery. However, a recent study found that 1 in 5 U.S. pharmacies do not provide the drug.
The DEA does not have a threshold for the drug, but it requires wholesalers to flag suspicious orders by creating detection algorithms. Studies in North Carolina and Kentucky found that many pharmacists worry that ordering enough buprenorphine to fit their communities’ needs will lead to a DEA investigation.
“Pharmacies are terrified they’re going to lose their DEA registration and go out of business,” Charles “Buck” Selby, a former inspector and chief compliance officer for the West Virginia Board of Pharmacy, told NPR.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.